

WO 2005/003149

BEST AVAILABLE COPY

PCT/GB2004/002906

8

CLAIMS

1. A process of preparing finasteride Form I, which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a non-solvent and thereafter isolating finasteride Form I.
2. A process according to claim 1, wherein replacement of said solvent comprises distilling off said solvent followed by addition of said non-solvent.
3. A process of preparing finasteride Form I, which process comprises the steps of: (i) dissolving finasteride in a solvent to form a solution; (ii) distilling off the solvent from the solution obtained in step (i); (iii) adding a non-solvent to the product of step (ii); and (iv) isolating finasteride Form I.
4. A process according to any of claims 1 to 3, wherein said solvent is methanol or dichloromethane.
5. A process according to any of claims 1 to 4, wherein dissolution of said finasteride in said solvent is carried out at a temperature in the range of ambient to reflux.
6. A process according to any of claims 1 to 5, wherein a finasteride solution obtained further to addition of finasteride to said solvent is clarified using decolourising agents.
7. A process according to any of claims 1 to 6, wherein said non-solvent is water.
8. A process according to any of claims 1 to 6, wherein said non-solvent is an organic solvent in which the solubility of finasteride is not more than about 5%w/v.
9. A process according to claim 8, wherein said organic non-solvent is selected from the group consisting of hexane, heptane, octane, toluene, xylene, isobutyl acetate and isopropyl acetate.

WO 2005/003149

BEST AVAILABLE COPY

PCT/GB2004/002906

9

10. A process according to any of claims 1 to 9, which further comprises distillation following addition of said non-solvent.
11. A process according to any of claims 1 to 10, which further comprises stirring a precipitated product obtained further to addition of said non-solvent so as to obtain finasteride Form I.
12. A process of preparing finasteride Form I, which process comprises dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a non-solvent, stirring a precipitated product obtained further to addition of the non-solvent and thereafter isolating finasteride Form I.
13. Finasteride Form I prepared by a process according to any of claims 1 to 12.
14. Finasteride Form I having a purity of at least about 99.6%w/w.
15. Finasteride Form I having a purity of at least about 99.7%w/w.
16. Finasteride Form I having a purity of at least about 99.8%w/w.
17. A pharmaceutical composition comprising a therapeutically effective amount of finasteride Form I according to any of claims 13 to 16, together with one or more pharmaceutically acceptable carriers, diluents or excipients therefor.
18. Finasteride Form I according to any of claims 13 to 16, for use in therapy.
19. A method of inhibiting 5-alpha reductase in a patient in need thereof comprising administering to said patient an effective inhibitory amount of finasteride Form I according to any of claims 13 to 16.

BEST AVAILABLE COPY

WO 2005/003149

PCT/GB2004/002906

10

20. Finasteride Form I according to any of claims 13 to 16, for use in the manufacture of a medicament for inhibiting 5-alpha reductase.